[Rheumatic diseases in pregnancy].
Rheumatic diseases can influence the reproduction, the course of pregnancy and the development of the fetus. The inflammatory rheumatic disease itself can be modulated in its activity in terms of amelioration or exacerbation of the rheumatic symptoms. The associations between rheumatic diseases and pregnancy will be illustrated with rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and systemic lupus erythematosus as examples. Antirheumatic drug therapy during pregnancy and the breast feeding period has to be adapted critically.
Märker-Hermann
E
E
Klinik Innere Medizin IV (Rheumatologie, klinische Immunologie und Nephrologie), HSK Dr. Horst Schmidt Klinik GmbH, Wiesbaden. Elisabeth.Maerker-Hermann@HSK-Wiesbaden.de
Bauer
H
H
Gromnica-Ihle
E
E
D016736:Antiphospholipid Syndrome / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology; D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015535:Arthritis, Psoriatic / Q000276:immunology; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000196:embryology / Q000503:physiopathology; D000075202:Contraindications; D005260:Female; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000150:complications / Q000196:embryology / Q000503:physiopathology; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy / Q000503:physiopathology*; D011256:Pregnancy Outcome; D012216:Rheumatic Diseases / Q000188:drug therapy / Q000196:embryology / Q000503:physiopathology*; D013167:Spondylitis, Ankylosing / Q000503:physiopathology
D018501:Antirheumatic Agents